Cost Effectiveness of Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Drugs & Aging
- Vol. 21 (5) , 279-295
- https://doi.org/10.2165/00002512-200421050-00001
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Memantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving DonepezilJAMA, 2004
- Spotlight on Galantamine in Alzheimer???s Disease*Disease Management and Health Outcomes, 2003
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003
- Assessment of Health Economics in Alzheimer??s Disease (AHEAD)PharmacoEconomics, 2002
- An Outline For a Cost-Effectiveness Analysis of a Drug For Patients With Alzheimer??s DiseasePharmacoEconomics, 1998
- The Pharmacoeconomics of Dementia TherapiesDrugs & Aging, 1997
- Guidelines for Pharmacoeconomic StudiesPharmacoEconomics, 1997
- The Cost of Alzheimerʼs DiseasePharmacoEconomics, 1996
- Tacrine for Alzheimer??s DiseasePharmacoEconomics, 1995
- Principles of Pharmacoeconomic Analysis of Drug TherapyPharmacoEconomics, 1992